{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T18:15:31Z","timestamp":1788977731042,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T00:00:00Z","timestamp":1726272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T00:00:00Z","timestamp":1726272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Qilu Pharmaceutical Co., Ltd funded this study"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s12325-024-02981-z","type":"journal-article","created":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T09:02:25Z","timestamp":1726304545000},"page":"4153-4171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Iparomlimab, an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors: A Phase 1c Study"],"prefix":"10.1007","volume":"41","author":[{"given":"Jianping","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanmei","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yabing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huerxidan","family":"Niyazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baihui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,14]]},"reference":[{"key":"2981_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","volume":"20","author":"A Naimi","year":"2022","unstructured":"Naimi A, Mohammed RN, Raji A, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal. 2022;20:44.","journal-title":"Cell Commun Signal"},{"key":"2981_CR2","doi-asserted-by":"crossref","unstructured":"Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50.","DOI":"10.1038\/s12276-018-0191-1"},{"key":"2981_CR3","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/jcp.27172","volume":"234","author":"FK Dermani","year":"2019","unstructured":"Dermani FK, Samadi P, Rahmani G, Kohlan AK, Najafi R. PD-1\/PD-L1 immune checkpoint: Potential target for cancer therapy. J Cell Physiol. 2019;234:1313\u201325.","journal-title":"J Cell Physiol"},{"key":"2981_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223\u201349.","journal-title":"Annu Rev Pathol"},{"key":"2981_CR5","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","volume":"11","author":"C Robert","year":"2020","unstructured":"Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11:3801.","journal-title":"Nat Commun"},{"key":"2981_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21:28.","journal-title":"Mol Cancer"},{"key":"2981_CR7","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. Cancer Cell. 2020;37:443\u201355.","journal-title":"Cancer Cell"},{"key":"2981_CR8","doi-asserted-by":"publisher","first-page":"1167975","DOI":"10.3389\/fimmu.2023.1167975","volume":"14","author":"Q Yin","year":"2023","unstructured":"Yin Q, Wu L, Han L, et al. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023;14:1167975.","journal-title":"Front Immunol"},{"issue":"122","key":"2981_CR9","first-page":"72","volume":"2019","author":"JM Michot","year":"1990","unstructured":"Michot JM, Lazarovici J, Tieu A, et al. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage? Eur J Cancer (Oxford, England). 1990;2019(122):72\u201390.","journal-title":"Eur J Cancer (Oxford, England)"},{"key":"2981_CR10","doi-asserted-by":"crossref","unstructured":"Fan Y, Xu Y, Huang Z, et al. 29P A phase I, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics\/pharmacodynamics, antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced solid tumors. ESMO Open. 2023;8:","DOI":"10.1016\/j.esmoop.2023.100995"},{"key":"2981_CR11","doi-asserted-by":"crossref","unstructured":"Desai J, Deva S, Lee JS, et al. Phase IA\/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. J Immunother Cancer. 2020;8.","DOI":"10.1136\/jitc-2019-000453"},{"key":"2981_CR12","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/cac2.12068","volume":"40","author":"X-L Wei","year":"2020","unstructured":"Wei X-L, Ren C, Wang F-H, et al. A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors. Cancer Commun (London, England). 2020;40:345\u201354.","journal-title":"Cancer Commun (London, England)"},{"key":"2981_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10637-016-0411-2","volume":"35","author":"N Yamamoto","year":"2017","unstructured":"Yamamoto N, Nokihara H, Yamada Y, et al. Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors. Investig New Drugs. 2017;35:207\u201316.","journal-title":"Investig New Drugs"},{"key":"2981_CR14","first-page":"4259","volume":"11","author":"H Jiang","year":"2021","unstructured":"Jiang H, Li N, Wang H, et al. Assessment of TMB, PD-L1, and lymphocyte to monocyte ratio as predictive potential in a phase Ib study of sintilimab in patients with advanced solid tumors. Am J Cancer Res. 2021;11:4259\u201376.","journal-title":"Am J Cancer Res"},{"key":"2981_CR15","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41416-018-0100-3","volume":"119","author":"H Mo","year":"2018","unstructured":"Mo H, Huang J, Xu J, et al. Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. Br J Cancer. 2018;119:538\u201345.","journal-title":"Br J Cancer"},{"key":"2981_CR16","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1200\/JCO.2017.74.5471","volume":"35","author":"J-S Frenel","year":"2017","unstructured":"Frenel J-S, Le Tourneau C, O\u2019Neil B, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. J Clin Oncol. 2017;35:4035\u201341.","journal-title":"J Clin Oncol"},{"key":"2981_CR17","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ygyno.2021.08.018","volume":"163","author":"DM O'Malley","year":"2021","unstructured":"O\u2019Malley DM, Oaknin A, Monk BJ, et al. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and\/or metastatic cervical cancer. Gynecol Oncol. 2021;163:274\u201380.","journal-title":"Gynecol Oncol"},{"key":"2981_CR18","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ygyno.2020.08.026","volume":"159","author":"D Rischin","year":"2020","unstructured":"Rischin D, Gil-Martin M, Gonz\u00e1lez-Martin A, et al. PD-1 blockade in recurrent or metastatic cervical cancer: data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer. Gynecol Oncol. 2020;159:322\u20138.","journal-title":"Gynecol Oncol"},{"key":"2981_CR19","doi-asserted-by":"publisher","first-page":"S217","DOI":"10.1016\/j.annonc.2021.05.005","volume":"32","author":"M Ducreux","year":"2021","unstructured":"Ducreux M, Abou-Alfa G, Ren Z, et al. O-1 Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma. Ann Oncol. 2021;32:S217.","journal-title":"Ann Oncol"},{"key":"2981_CR20","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1200\/JCO.22.00620","volume":"41","author":"S Qin","year":"2023","unstructured":"Qin S, Chen Z, Fang W, et al. Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma: a randomized, double-blind, phase III trial. J Clin Oncol. 2023;41:1434\u201343.","journal-title":"J Clin Oncol"},{"key":"2981_CR21","doi-asserted-by":"crossref","unstructured":"Shen L, Guo J, Zhang Q, et al. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1\/2 study. J Immunother Cancer. 2020;8.","DOI":"10.1136\/jitc-2019-000437"},{"key":"2981_CR22","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S1470-2045(20)30023-1","volume":"21","author":"KL Davis","year":"2020","unstructured":"Davis KL, Fox E, Merchant MS, et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1\u20132 trial. Lancet Oncol. 2020;21:541\u201350.","journal-title":"Lancet Oncol"},{"key":"2981_CR23","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ejca.2020.01.028","volume":"130","author":"J Yang","year":"2020","unstructured":"Yang J, Dong L, Yang S, et al. Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study. Eur J Cancer (Oxford, England: 1990). 2020;130:182\u201392.","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"key":"2981_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-018-0693-2","volume":"12","author":"B Tang","year":"2019","unstructured":"Tang B, Yan X, Sheng X, et al. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. J Hematol Oncol. 2019;12:7.","journal-title":"J Hematol Oncol"},{"key":"2981_CR25","doi-asserted-by":"crossref","unstructured":"Naing A, Gainor JF, Gelderblom H, et al. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors. J Immunother Cancer. 2020;8.","DOI":"10.1136\/jitc-2020-000530"},{"key":"2981_CR26","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1038\/s41416-022-02001-3","volume":"127","author":"S Qin","year":"2022","unstructured":"Qin S, Li J, Zhong H, et al. Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial. Br J Cancer. 2022;127:2241\u20138.","journal-title":"Br J Cancer"},{"key":"2981_CR27","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00280-022-04414-6","volume":"89","author":"E Felip","year":"2022","unstructured":"Felip E, Moreno V, Morgensztern D, et al. First-in-human, open-label, phase 1\/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. Cancer Chemother Pharmacol. 2022;89:499\u2013514.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2981_CR28","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00262-020-02730-5","volume":"70","author":"KP Papadopoulos","year":"2021","unstructured":"Papadopoulos KP, Lakhani N, Falchook GS, et al. Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors. Cancer Immunol Immunother. 2021;70:763\u201372.","journal-title":"Cancer Immunol Immunother"},{"key":"2981_CR29","doi-asserted-by":"crossref","unstructured":"Patnaik A, Weiss GJ, Rasco DW, et al. Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial. Cancer Chemother Pharmacol. 2022;89.","DOI":"10.1007\/s00280-021-04358-3"},{"key":"2981_CR30","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","volume":"14","author":"R Berger","year":"2008","unstructured":"Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008;14:3044\u201351.","journal-title":"Clin Cancer Res"},{"key":"2981_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s13046-022-02383-5","volume":"41","author":"SL Chan","year":"2022","unstructured":"Chan SL, Schuler M, Kang Y-K, et al. A first-in-human phase 1\/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. J Exp Clin Cancer Res. 2022;41:189.","journal-title":"J Exp Clin Cancer Res"},{"key":"2981_CR32","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/jcph.818","volume":"57","author":"S Agrawal","year":"2017","unstructured":"Agrawal S, Statkevich P, Bajaj G, et al. Evaluation of immunogenicity of nivolumab monotherapy and its clinical relevance in patients with metastatic solid tumors. J Clin Pharmacol. 2017;57:394\u2013400.","journal-title":"J Clin Pharmacol"},{"key":"2981_CR33","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/s41416-022-02128-3","volume":"128","author":"J Desai","year":"2023","unstructured":"Desai J, Fong P, Moreno V, et al. A Phase 1\/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours. Br J Cancer. 2023;128:1418\u201328.","journal-title":"Br J Cancer"},{"key":"2981_CR34","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12943-018-0864-3","volume":"17","author":"M Yi","year":"2018","unstructured":"Yi M, Jiao D, Xu H, et al. Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors. Mol Cancer. 2018;17:129.","journal-title":"Mol Cancer"},{"key":"2981_CR35","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823\u201333.","journal-title":"N Engl J Med"},{"key":"2981_CR36","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","volume":"129","author":"W Ding","year":"2017","unstructured":"Ding W, LaPlant BR, Call TG, et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017;129:3419\u201327.","journal-title":"Blood"},{"key":"2981_CR37","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","volume":"17","author":"P Sharma","year":"2016","unstructured":"Sharma P, Callahan MK, Bono P, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial. Lancet Oncol. 2016;17:1590\u20138.","journal-title":"Lancet Oncol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02981-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02981-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02981-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T18:09:46Z","timestamp":1729015786000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02981-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,14]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["2981"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02981-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,14]]},"assertion":[{"value":"19 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yan Chen, Baihui Zhang, Lingyan Li, Xiaoyan Kang are affiliated with the sponsoring entity. Their involvement does not influence the integrity and objectivity of the research findings presented in this study. Jianping Xiong, Weiwei Ouyang, Mengxiang Yang, Zhenyuan Gao, Huan Zhou, Hanmei Lou, Yabing Guo, Zhongyuan Xu, Ling Zheng, Ying Liu, Zhongfeng Wang, Ping Sun, Huerxidan Niyazi, Jianhua Wang, and Weijian Guo declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol was approved by Fudan University Shanghai Cancer Center Institutional Review Board (No.2006219-10-2007) and the First Affiliated Hospital of Nanchang University Institutional Review Board (No.2020-029). This study was conducted in compliance with the protocol, and in accordance with the principles of the Declaration of Helsinki as well as the Good Clinical Practice guidelines. This study was registered with clinicaltrials.gov (identifier, NCT05801094).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}